4,7,11,14-Hexadecatetraenoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 4,7,11,14-Hexadecatetraenoic acid
• 英文别名: (4E,7E,11E,14E)-hexadeca-4,7,11,14-tetraenoic acid
• 化学式: C₁₆H₂₄O₂
• 分子量: 248.36
• InChiKey: ZZNKKFHDVFOAEZ-VAAAAXNRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  18
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• PHARMACEUTICAL COMPOSITION AND METHODS
  申请人：Lipocine Inc.

  公开号：EP3185873A1

  公开（公告）日：2017-07-05
• (17-ß)-3-OXOANDROST-4-EN-17-YL UNDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
  申请人：Lipocine Inc.

  公开号：US20160193225A1

  公开（公告）日：2016-07-07

  Disclosed herein are compositions having a lipophilic active agent and methods of their use.
• (17-ß)-3-Oxoandrost-4-En-17-Yl Undecanoate Compositions and Methods of Their Preparation and Use
  申请人：Lipocine Inc.

  公开号：US20180104257A1

  公开（公告）日：2018-04-19

  Disclosed herein are compositions having a lipophilic active agent and methods of their use.
• [EN] (17-β)-3-OXOANDROST-4-EN-17-YL UNDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE<br/>[FR] COMPOSITIONS D'UNDÉCANOATE DE (17-Β)-3-OXO-ANDROST-4-ÉN -17-YLE, ET PROCÉDÉS DE PRÉPARATION ET D'UTILISATION DE CEUX-CI
  申请人：LIPOCINE INC

  公开号：WO2016033611A1

  公开（公告）日：2016-03-03

  Disclosed herein are compositions having a lipophilic active agent and methods of their use. This invention further discloses substantially pure (17-beta)-3-0xoandrost-4-en-17-yl undecanoate includes (17-beta)-3-0xoandrost-4-en-17-yl undecanoate substantially free of synthetic impurities, decomposition impurities or both.
• [EN] PHARMACEUTICAL COMPOSITION AND METHODS<br/>[FR] COMPOSITION PHARMACEUTIQUE ET PROCÉDÉS
  申请人：LIPOCINE INC

  公开号：WO2016033536A1

  公开（公告）日：2016-03-03

  A compositions and dosages forms that allow for high drug loading for highly lipophilic drugs while maintaining excellent oral bioavailability. The pharmaceutical compositions and unit dosage forms described herein can reduce pill burden for hydrophobic drugs like(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9, 11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl tridecanoate or (8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-l,2,6, 7,8,9,11,12,14,15,16,17- dodecahydrocyclopenta[a]phenanthren-17-yl tetradecanoate, and can be formulated at advantageous drug loads (e.g., greater than 23%) while providing suitable bioavailability (e.g., capable of treating a hypogonadal male with less than 10 unit dosage forms per day) that allows for reduction in pill burden and accordingly improved patient adherence or compliance. Additionally, the composition (e.g., dosage form) has a release profile that is suitable for providing bioavailable API and the release profile is stable over time (e.g., under storage conditions).